Company intelligence / Profile preview

Dabur Research Foundation

Ownership: Private
Development stage: Preclinical

Overview

Dabur Research Foundation provides end-to-end preclinical development services including in vitro and in vivo pharmacology, mechanistic profiling, translational disease models, analytical and formulation development services up to regulatory toxicology. They support IND-enabling studies for new chemical entities (NCEs), biologicals/biologics, phytopharmaceuticals and generics. The company leverages over 30 years of drug discovery experience from its origins within the Dabur group. As a CRO they do not have their own clinical pipeline or results.

Therapeutic areas: OncologyImmunologyOtherDermatologyGastroenterologyNeurology
Modalities: Small moleculeBiologicPhytopharmaceuticalGeneric molecule
Industry: Contract Research Organization

Beyond the preview

Go deeper on Dabur Research Foundation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dabur Research Foundation.

Explore the full profile